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Mechanical ventricular assistance as
destination therapy for end-stage
heart failure: has it become a first line
therapy?
Massimo Bonacchi*, Guy Harmelin, Marco Bugetti and Guido Sani
Cardiac Surgery, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Patients with end-stage heart failure have poor quality of life and prognosis. Therapeutic
options are scarce and are not available for all. Only few patients can be transplanted
every year. Several medical and surgical strategies have shown limited ability to
influence prognosis and quality of life. In the past years, technological progress has
realized devices capable of providing appropriate hemodynamic stabilization and
recovery of secondary organ failure. Recently, these devices have been assessed as
definitive treatment for patients who do not qualify for transplantation or/and instead to
transplantation (“destination therapy”). This indication is increasingly considered following
the results of newest clinical study reporting long-term survival without device correlated
adverse events using last generation devices, and acceptable quality of life. The current
knowledge about destination therapy and some original data from the DAVID Study
(an Italian multicenter prospective study designed to evaluate the patient’s survival rate
and quality of life of patients implanted with these new devices as long-term support or
destination therapy) are summarized herein.
Key Points
– End-stage heart failure (NYHA class IV or stage D) is a vastly growing problem, with a
poor prognosis and limited therapeutic options.
– Heart Transplantation is nowadays the “gold standard” treatment albeit its inability to
serve to the current demand let alone the future one.
– The REMATCH study has demonstrated that first generation implantable devices,
even with their high number of complications (infectious and thromboembolic events),
allowed an improvement of quality and duration of life compared to medical therapy.
Further studies have shown that the evolution of VAD technology has reduced device-
related complications and consequently improved survival and quality of life of patients
with results, according to some authors, similar to cardiac transplantation at least at
2 years from the implantation.
– Biotechnology advancements have led to the creation of a new generation of
implantable mechanical assist devices: the continuous-flow rotary pumps. Recently
entered into clinical use, they seem to represent a promising solution to end -stage
Frontiers in Surgery | www.frontiersin.org August 2015 | Volume 2 | Article 351
Bonacchi et al. The promise of destination therapy
– heart failure allowing long-term assistance and an adequate standard of living
(Destination Therapy/Bridge to Life).
– The DAVID Study, an Italian multicenter prospective study, reports encouraging results
in terms of late outcome and quality of life in patients implantedwith newest continuous-
flow devices as destination therapy. More and more numerous studies are needed
to confirm our initial data and for laying the foundations for this new therapeutic frontier
face to cardiac transplantation.
Keywords: end-stage heart failure, ventricular assist devices, heart transplantation, destination therapy, quality
of life
Introduction
Advanced heart failure is an epidemic contributing considerably
to the overall cost of health care in developed nations. The number
of people afflicted with this complex syndrome is increasing at
an alarming pace with this trend will likely continue for many
years.
End-stage heart failure may present as an acute event or as the
terminal stage of a chronic heart disease. In its acute refractory
form, initiating mechanical support relies heavily on the assess-
ment of the recovery potential of cardiac function and the patient’s
possibility to be a candidate for transplantation or definitive
mechanical assistance.
In the case of patients with terminal chronic heart failure,
the therapeutic procedure is more complex. We are faced with
patients who have poor prognosis and poor quality of life as
encumbered by the presence of symptoms even at rest, require
frequent hospitalizations and have complex, difficult to manage
drug therapies. In this cohort of patients, the quality of life is very
poor and mortality rate at 1 year that is approximately 50% (1,
2). Key treatment is heart transplant: with more than 85% 1-year
survival and approximately 70–75% survival at 5 years, according
to the registry of the International Society for Heart and Lung
Transplantation (3). It is now clear that transplantation alone
cannot meet all its demand and the availability of hearts for trans-
plantation will always be a limited resource. Furthermore, even
after optimizing the rate of donations per million inhabitants with
the increase of older donors will not increase the actual availability
of transplantable hearts (4). Moreover, the transplanted hearts are
not immune to complications, with implications in survival and
quality of life: this is evident from the data register collected by the
International Society of Heart and Lung Transplantation (ISLHT)
(see Tables 1 and 2) (3).
Other therapies, bothmedical and surgical, show limited ability
to affect the prognosis and quality of life (1, 4, 5).
The quite recent introduction of next generation left ventricu-
lar assist devices (VAD), which guarantee operational reliability
for long periods, small footprint, and excellent quality of life,
has changed the treatment possibilities for these patients (6–8).
Based on latest clinical experience, we can now implant these
new “artificial ventricles” in patients who have contraindications
to transplantation. The future perspective is to realize a “Desti-
nation Therapy” and a “Bridge to Life” in these patients with a
survival potential and quality of life similar if not better than the
transplantation.
TABLE 1 | Prevalence of complications at 5 and 10 years in patients with
heart transplant (modified by 2014 ISHLT Registry).
Complications After 5 years (%) After 10 years (%)
Hypertension 92 : : :
Renal failure 52 68
Abnormal creatinine <2.5mg/dl 33 39
Creatinine >2.5mg/dl 15 20
Dialysis 3 6
Renal transplant 1.1 3.6
Dyslipidemia 88 : : :
Diabetes 38 : : :
Cardiac allograft vasculopathy 30 50
TABLE 2 | Prevalence of malignant tumors at 1, 5, and 10 years after heart
transplantation (modified by 2014 ISHLT Registry).
Tumors At 1 year (%) At 5 years (%) At 10 years (%)
Absence of tumors 97.4 85.8 72.3
Tumors (all types) 2.6 14.2 27.7
Type of tumors
Skin 1.3 9.4 19.6
Lymphatic 0.5 1.1 1.7
Other 0.6 4.1 8.7
Unspecified 0.2 0.3 0.3
The initial data coming out of the DAVID study, a multicenter
prospective clinical trial, as other worldwide similar studies data,
designed to evaluate the survival and quality of life in patients with
end-stage failure VAD-supported seem to support this encourag-
ing perspective.
Development of Ventricular Assist Devices:
From Extracorporeal Pulsatile Pneumatic
Pumps to Intra-Ventricular
Continuous-Flow Rotational Pumps
The possibility of replacing human organs with artificial organs
has stimulatedmedical research since the beginning of the twenti-
eth century. In the 60s, with the advent of the heart–lung machine
and the increased number of complex cardiac interventions, came
a boost in development of systems for temporary ventricular assis-
tance: In 1963, DeBakey implanted the intra-thoracic first pump
in a 42-year-old man who had underwent an aortic valve replace-
ment complicated by post-cardiotomy syndrome. For many years,
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TABLE 3 | Issues with cardio-circulatory assist devices.
The energy source, consisting of very large and heavy compressors
Bulky and short life batteries
The thrombogenicity of the contact surface with circulating blood
The size of the device, too big to consider for long-term intra-thoracic implantation
The need for extensive connectivity measures with the exterior in order to connect
the device to the energy source and to the controller
The high rate of bleeding complications and infectious diseases
the improvements were only partial and, in fact, both short-
and long-term devices were implanted only in a few dedicated
centers, which even in highly selected patients were unable to
obtain satisfactory results. The major problems encountered were
linked to specific factors including inadequate biocompatibility
(see Table 3). As technology advanced many of these issues have
been resolved and various new devices have been redesigned and
marketed for clinical use.
The initial concept with pulsatile-flow pumps was to construct
a device that would mimic blood flow as close as possible to
the human physiology. The blood volume was moved by means
of a pneumatic system driven by a compressor. The first clini-
cal application was implemented with extracorporeal systems, in
which the pump and the source of energy were placed outside
of the patient body. The ventricles were connected by means of
cannulae and could replace the left ventricular function, right
or both depending on clinical needs. Assistance could last for a
relatively short period (up to a few weeks). It was burdened by a
high rate of complications and required the patient to stay in his
bed at all times. The patients could only be partiallymobilized and
they remained hospitalized until transplantation.
Second to come were the para-corporeal systems. Here, the
power source was external and the pump was fixed to the patient’s
external surface, which could, thanks to the development of
smaller compressors, get out of bed and walk around. These
systems can provide both mono- and bi-ventricular support and
can be used both as a “bridge to transplantation” and as a “bridge
to recovery” and are still used to date.
Further significant advancement was represented by intra-
corporeal systems; totally implantable pulsatile-flow pumps, fed
first via pneumatic systems, and subsequently electrically. These
are devices are used exclusively for left ventricle assistance. The
implant, due to its size is must be placed in the abdominal cavity
and can be intra- or extra-peritoneal. The connection ismadewith
the heart’s chambers via cannulae connected to the left ventricle
and the aorta. A percutaneous cable is used to connect the device
to an external power supply and control unit. The most advanced
models used to date are Novacor andHeartMate I XVE (Figure 1).
Major issues presented in this category are size, which make it
difficult to implant, the presence of large external connection lines
that may be due to cause frequent infections (30–50% of cases),
and thromboembolic events (9, 10).
This group of devices presented for the first time the pos-
sibility for a true bridge to transplantation with thousands of
cases, with one reaching more than 6 years of life (11). In contrast
to the first generation of pulsatile pneumatic and after, electric
pumps, substantial development has led to the construction of
non-pulsatile, miniaturized rotational pumps. Electrically pow-
ered continuous-flow pumps are based on a rotating system that
creates propulsive energy driving a continuous flow of blood. For
many years, it was thought that this type of flow is not tolerable
for long periods in mammals. This presumption has been rebutted
by all preclinical and clinical studies carried out (12, 13). Several
types of pumps exist, such as extracorporeal and para-corporeal
systems commonly called “centrifugal pumps” and used primarily
as a circulatory support systems in the short/medium term, i.e., as
a bridge to definitive treatment (Jostra Rotaflow, TandemHeart,
Levitronics Centrimag). Continuous-flow pumps of rotary type
with or without mechanical suspension (in this case generally
centrifuge) were the first to be proven effective in clinical use and
particularly suitable for assistances of medium and long duration
(destination therapy). These devices are of limited size with a rotor
wing that rotates at variable speeds (5,000/12,000 rpm) and gener-
ates a flow rate of up to 10/12 l/min., having significant advantages
(14–17) (see Table 4). The main advantage is the use of minimally
invasive implantation techniques (mini-access, beating heart and,
eventually, without CPB) with considerable reduction of surgical
trauma (Figure 2). As regards the long-term impact, it seems that
the continuous flow is well tolerated. Initially, for a few weeks,
patients may experience changes in baroreceptor activity, in the
release of catecholamines, the lymphatic pumps, renal cortex flow,
and vascular permeability. Potentially contributing to a certain
degree of fluid retention and edema that usually resolves itself in
a short time. It has also been shown that there is a reduction of
the oxygen consumption of 20% and an increase in the coronary
flow (12).
Among them, the first to receive FDA approval for Destination
therapy in 2010 wasHeartMate II LVAS (in 2008 was approved for
“bridge to transplantation”) (Figure 3).
The Jarvik 2000 Flowmaker, is the smallest VAD, to date,
applicable for total ventricular assistance as destination therapy
(5.5 cm in length and 90 g of weight); it is for many aspects, a
peculiar system within the axial devices group, with advantages
thatmake it today one of themost safe and reliable (Figure 4). The
device is completely housed inside the left ventricle with a duct
outflow anastomosed to the descending aorta making it extremely
“integrated” both anatomically and functionally with the ventricle
(7, 16, 17), thus, substantially reducing the space and surfaces in
contact with blood.
First in Europe (2005) and recently in United States (2012), the
FDA approved a trial to evaluate the Jarvik 2000® for destination
therapy indication called – Randomize Evaluation of Long-term
Effectiveness intra-ventricular VAD (RELIEVE). It is the only
approved system for clinical use that has its power supply system
implanted behind the ear, on the left temporal bone. This tech-
nique (derived from cochlear implants) has shown considerable
advantages in terms of resistance to infection and management
by the patient, with consequent improvement in the quality of
life for patients in which the indication is an alternative to heart
transplantation.
“Third generation support devices,” already in clinical use, are
smaller rotational pumps, designed with a magnetic levitating
rotor (similar to a propeller). These pumps are simple in main-
tenance and at the same time less harmful to blood cells, thereby
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FIGURE 1 | Fully implantable pulsatile ventricular assist devices: to the left Novacor (Source: World Heart, www.worldheart.com, accessed December
31, 2014.), to the right HeartMate I XVE (Source: Thoratec, www.Thoratec.com, accessed December 31, 2014.).
TABLE 4 | Main differences between ventricular assist devices (VAD) with
pulsatile flow and VADs with continuous flow.
Advantages of continuous-flow VADs versus pulsatile-flow VADs
Smaller dimensions (better compliance and easier implantation)
Simple structure with fewer moving parts (less risk of mechanical failure)
No filling chamber (less chance of stasis and thromboembolic events)
Reduced energy consumption (smaller batteries and greater autonomy)
Hypothetic disadvantages (with negative clinical implications – unproven)
A certain degree of hemolysis, usually well tolerated by patients
The long-term effects of systemic non-pulsatile flow are still not known
Control mechanisms (feedback) of the speed of the pump, and therefore, the flow
generated are complex and not yet optimized
FIGURE 2 | Size comparison between pulsatile-flow VAD (left) and
continuous-flow VAD (to the right).
reducing hemolysis. The blood flow is not axial (inflow and out-
flow axes are arranged in a 90° angle) and they run with lower
rotation speed of 1000–2500/min. The moving part “impeller,”
spins blood to generate up to 10 l/min of blood flow. The pump is
connected to the controller via a thin driveline, which is tunneled
just the upper right quadrant of the abdomen. Two examples of
third generation devices that are clinically employed are as follows:
 Berlin Heart Incor pump: this device uses magnetic suspension
technology preventing any contact between the rotor and fixed
components. The pump weighs 200 g and has a diameter of
3 cm and a length of 12 cm. It generates a flow of blood up to
14 l/min. The connecting lines to the battery and control unit
pass through the abdominal wall with the inner surface of the
device coated with heparin (Figure 5);
 HVAD (HeartWare Corp.): with a displacement volume of
45ml, and weight 145 g this device has a flow capacity of up
to 10 l/min. The HVAD uses a wide-blade impeller design to
maximize performance and hemocompatibility, size minimiza-
tion, long-term reliability, and overall system efficiency. The
impeller is suspended in place by combination of passive mag-
netic and hydrodynamic bearing systems to avoid mechanical
contact and wear. The impeller suspension system uses a pas-
sivemagnetic bearing for radial stiffness. The axial alignment of
the center-post magnet stack is set to provide an axial force that
pushes the impeller toward the forward housing (the assembly
with the inflow cannula). Physical contact between the housing
and the impeller is prevented by a thin blood-film generated
by the hydrodynamic bearings. The hydrodynamic bearings
feature a shrouded design that is intended to maximize the
blood-film thickness and improve surface washing (Figure 6).
Total Artificial Heart
The total artificial heart (TAH) is the most advanced implantable
pump system. As first VAD devices, it is mostly used as a
“bridge to transplant.” It is necessary to ensure a balance between
stroke volumes of both ventricles and adjust the flow generated
to the physiological needs. Among the TAH s available, two
are in an advanced stage of experimentation and approved by
the FDA: The Abiomed AbioCor Total Artificial Heart and the
Jarvik 7-CardioWest (Figure 7). At the moment, their clinical
use is limited, albeit an important development is expected the
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FIGURE 3 | HeartMate II (Source: Thoratec, www.Thoratec.com, accessed December 31, 2014.).
FIGURE 4 | Jarvik 2000 Flowmaker. In the boxes, specific aspects of the device: intra-ventricular system, retro-auricular fitting (Source: JarvikHeart,
www.jarvikheart.com, accessed December 31, 2014.).
near future. The indications are reserved for patients waiting
for a heart transplant for which any other type of assistance are
excluded. The most experienced cardiac surgery center with TAH
implantation is Bad-Oeynhausen in Germany, with more than
160 CardioWest devices implanted and an operative mortality
at approximately 67% due to the extremely severe conditions of
patients (18).
Recently, a new TAH, the CARMAT (Carmat, Velizy, France)
(Figure 8), was introduced for clinical use with the ambition to
became the first TAH used for “Destination therapy.” The first
CARMAT was implanted in December 2013 (the patient died
after 75 days due to a device failure), the second implanted in
August 2014 with the patient currently home. The device contains
two ventricles, each with a blood compartment and a driving
fluid compartment, separated by a flexible hybrid membrane (in
polyurethane). All the blood-contacting surfaces are covered with
bovine pericardial tissue with the use of bio-prosthetic valves at
the inlet and outlet of each blood compartment. Thismight permit
a reduction of anti-coagulation therapy. Electro-hydraulic pumps
create a systolic and a diastolic phase by moving the silicone fluid
and deploying themembrane. The stroke volume and the beat rate
of the prosthesis adapt automatically in response to changes in
preload, detected by the pressure sensors located in the device.
The resulting pulsatile blood flow ranges from 2 to 9 l/min with
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FIGURE 5 | Berlin Heart Incor (Source: Berlin Heart,
www.berlinheart.com, accessed December 31, 2014.).
a flow adjustment on the right side to correct for the bronchial
shunt. A percutaneous driveline delivers power to the prosthesis
and allows exchange of data and inputs. This implantable pros-
thesis is still quite large, it weighs 900 g; studies performed by the
manufacturer claimed that it fits 65% of patients (86% of which
were men) (19, 20).
Clinical Use of Cardio-Circulatory Assist
Devices: Indications and Strategies for
Implantation
It is true that the criteria for implantation of the cardiovascular
assist systems are not fully defined because there are not enough
established clinical trials (21–23). There is, however, strong evi-
dence that may serve as guidelines. Mechanical assistance is used
mainly in cases of post-cardiotomic shock or other acute situa-
tions in which we consider the possible recovery of cardiac func-
tion (bridge to diagnosis, bridge-to-bridge, or bridge to recovery)
(24–26) or in terminal patients with conditions that do not allow
transplant due to critical state, in order for them to recover from
shock and multi-organ failure, making them candidates for trans-
plantation (bridge to transplantation or bridge to candidacy) (26–
28). In such cases, it may be necessary to support a single ventricle
or bi-ventricular. The results depend on the complications related
to mechanical assistance and medical condition of the patient at
implantation.
The encouraging results obtained with pulsatile electric VAD
(5, 9, 21), further improved with the use of continuous-flow
pumps (6, 13, 16, 17), allowus to take into account the use ofVADs
as definitive therapy or “destination therapy” in order to obtain
“Return to Normal Life” or “Bridge to Life.” There is also the pos-
sibility, at the moment demonstrated only in a selected category
of patients, to obtain some sort of “reverse remodeling” favored by
FIGURE 6 | The HVAD (HeartWare Corp.) ventricular assist device.
(Source: http://www.carmatsa.com/, accessed December 31, 2014.).
decompression and functional rest of the cardiac cavities (23–26,
29–31).
In summary, the following potential goals of mechanical circu-
latory support can be defined according to the intention and the
clinical situation:
1. Bridge to decision or bridge-to-bridge;
2. Bridge to recovery;
3. Bridge to candidacy;
4. Bridge to transplant;
5. Destination therapy.
Destination Therapy: Current Perception
and Clinical Implications of Cardiovascular
Mechanical Assistance
The best estimates for the number of patients under the age
of 65 years with chronic heart failure in the pre-terminal assess
around 250,000 in the U.S. and 10,000 in Italy. Only 2000/2300
in the USA and 200/250 in Italy heart transplants are performed
each year (1, 4, 7, 8). The difference, in theory, should be covered
by mechanical devices. These numbers will increase several fold
when we will start considering as candidates patients in NYHA
class 3b and move the age limit to 75 years (4).
Rarely will we evaluate the possibility of a VAD implantation as
a viable alternative to transplantation, often for economic reasons
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FIGURE 7 | Two devices approved by the FDA for the complete replacement of the heart, the Jarvik-7-CardioWest (left) (Source JarvikHeart,
www.jarvikheart.com, accessed December 31, 2014) and the AbioCor (right) (Source: AbioCor, www.abiomed.com, accessed December 31, 2014).
FIGURE 8 | The CARMAT (Carmat, Velizy, France) total artificial heart (Source: CARMAT, www.carmat.com, accessed December 31, 2014).
since its relatively initial high cost. Thus, without considering
the savings in terms of hospitalization and therapy with trans-
planted patients. Furthermore, there is lack of confidence in the
presented results in the literature as there are no randomized trials
that compare the different devices available. There are, however,
observational studies that are of high significance.
The “Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure” (REMATCH) study (9)
and “Investigation of Non-Transplant-Eligible Patients who are
inotrope Dependent study” (INTREPID) (32) evaluated, in this
regard, the two electrical, pulsatile, totally implantable VADs who
had been most used clinically to that date: HeartMate I and
Novacor.
The results of the REMATCH study (10) show that the survival
of the VAD group compared to the medical therapy group, at
1 year are 52 versus 25% (p= 0.002), and at 2 years 23 versus
8% (p= 0.09). Moreover, there is a marked improvement in the
quality of life in the VAD patients (Table 5).
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TABLE 5 | Evaluation of quality of life in the two groups using rating scales
of physical and mental wellbeing.
Scale used Evaluation at 1 year p
Patients evaluated/
total (%)
Score
Short form 36 questionnaire
Physical state 0.01
LVAD group 23/24 (96) 4619
Medial therapy group 6/11 (55) 2121
Emotional state 0.001
LVAD group 23/24 (96) 6445
Medial therapy group 6/11 (55) 1728
Minnesota living with HF 0.11
LVAD group 23/24 (96) 4122
Medial therapy group 6/11 (55) 5821
Beck depression inventory 0.04
LVAD group 22/24 (92) 87
Medial therapy group 5/11 (45) 137
Classe NYHA media <0.001
LVAD group 22/24 (100) II
Medial therapy group 7/11 (64) IV
Modified by Rose et al. (9).
These results compared with those of transplanted patients do
not seem exciting (3), it is necessary however to consider the
severity of the patients conditions and their older age (average
age is 65 years). Several of the deaths reported were related to dys-
functions of the device itself (35%), infections of the percutaneous
abdominal the driveline (41%) and to further cerebrovascular
events (10%) (Table 6). Similar results have been reported from
the study INTREPID (33).
A subsequent study (6) of 309 patients implanted between
November 2002 and December 2005 and included in the FDA
Destination Therapy Registry, divided the patients into two cat-
egories, high and low risk. Survival is 81 and 11% at 1 year and
48 and 0% at 2 years, demonstrating the need for a more careful
patient selection. Another study (22) using the database of the
REMATCHstudy divided its patients into two groups according to
the period of implantation (1998–1999 and 2000–2001) and eval-
uated the outcomes and adverse events. This analysis deducted
that a more careful selection and management of patients allowed
better results; at 1 year 59 versus 44% and at 2 years of 38 versus
21% (p= 0.029).
Clinical Implications of New Generation
VADs: Devices with Continuous Axial Flow
The clinical introduction of VAD’s has allowed us to confirm
preclinical data on the possible use of the continuous flow (12–
14), and the important advantages in terms of efficiency, dura-
bility, thromboembolic complications, and infections (6, 7, 14,
16, 28). These advantages were confirmed by a study of 133
patients (NYHA class IV and UNOS status I and an average age
of 50 years), which were implanted with axial pumps (HeartMate
II). After 180 days, 100 patients (75%) achieved a major outcome
of the study (cardiac transplantation, recovery of cardiac function
TABLE 6 | Causes of death in both groups.
Cause of death Group medical
therapy
Group
LVAD
Total
Number of patients
Left ventricular dysfunction 50 1 51
Sepsis 1 17 18
Failure of VAD 0 7 7
Non-cardiovascular causes 0 5 5
Cerebrovascular events 0 4 4
Other cardiovascular causes 1 2 3
Pulmonary emboli 0 2 2
Acute myocardial infarct 1 0 1
Cardiac procedure 1 0 1
Operational bleeding 0 1 1
Unknown 0 2 2
Total 54 41 95
Modified by Rose et al. (9).
or survival with mechanical support active). Furthermore, com-
pared to the REMACTH study, there was a significant decline in
complications: infections went from 3.49 to 0.37, stroke from 0.67
to 0.26; neurologic events from 0.67 to 0.26; and right ventricular
failure from 0.30 to 0.08. This data are a prerequisite for the
hypothesis for using VADs as an alternative to transplantation,
especially of symptomatic patients (15, 19). The reliability of
the system is demonstrated by the experience carried out in the
year 2000 with a Jarvik device in a male patient of 60 years (16)
who suffered from idiopathic dilated cardiomyopathy with severe
terminal heart failure. Immediately after implantation, the patient
regained an acceptable clinical condition and after about three
months was inNYHA class I. He remained free of events related to
the device for 7.5 years. His quality of life was excellent. The cause
of death was not related to the device, as confirmed by the autopsy.
It showed the perfect integrity of the pump and the absence of
thrombotic appositions on it (7, 16).
Despite all efforts to optimize cardiac support devices some
complications still occur throughout the period of support:
– Bleeding, particularly in the peri-operative period, but rarely
disastrous with new devices (34)
– Cerebral, Gastrointestinal bleeding, and peripheral thromboem-
bolic complications (35, 36), strictly correlated with the contin-
uous flow that seem to promote gastrointestinal bleeding due to
angiodysplasia or arteriovenous malformations and appears to
be related to the different flow characteristics of these devices
(37) and the anti-coagulation regimen administration (38). The
pathophysiological mechanism seems to be related to the shear
stress of continuous-flow devices that may cause proteolysis of
the Von Willebrand factor. In addition, there is a prolonged
activation of the fibrinolytic system, and some loss of platelets.
In order to decrease the incidence of such events, screening for
vonWillebrand disease and gastrointestinal pathologies may be
indicated before implantation of such LVAD systems.
– Infections are the most frequent complication in patients with
a mechanical circulatory support system. Predisposing factors
for local wound infection are age, diabetes, tension on the
wound edges, and localized hematoma followed by bacterial
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colonization (39). Infection is often linked to the percutaneous
driveline. The method of bone fixation seems to reduce drasti-
cally this nasty complication. One essential technical progress
needed to optimize the destination option and simplify the
daily life of such patients is the so-called “Transcutaneous
Energy Transfer System” thus avoiding altogether the percuta-
neous energy driveline.
– Right ventricular failure and life-threatening arrhythmias (40).
Playing a key point in the isolated left ventricular mechanical
assistance: right ventricular failure is one of the most impor-
tant causes of peri-operative and early postoperative mortal-
ity and morbidity following LVAD implantation: changes that
occur after initiating left ventricular support should be followed
very closely during early post-implant management in ICU.
Echocardiography has clearly shown that after LVAD assistance
started, the interventricular septum is pulled to the left and
the RV free wall is distended. Before LVAD implantation, it is
therefore very important to optimize RV function, but while
pulmonary hypertension and the risk of severe RV failure are
someof themajor concerns during the assessment of candidates
for “bridge to transplantation” these factors is only of modest
importance in the setting of destination therapy. Implantation
of a LVAD will typically lead to a significant decrease of pul-
monary pressure and secondarily of right atrial pressure (28).
Recently, an RV failure risk score (RVFRS) was proposed by
Matthews et al. (41) composed of routinely collected, non-
invasive pre-operative clinical data (vasopressor requirement;
aspartate aminotransferase, bilirubin, and creatinine levels)
effectively stratifies the risk of RV failure and death after LVAD
implantation.
Different diagnostic tools have been proposed to evaluate accu-
rately pre-implantation right ventricular function. Recently
(42), we applied RV deformation analysis by speckle track-
ing echocardiography for a deeper analysis of RV longitudi-
nal function before and after LVAD implantation, founding
important clinical implications for selection and management
of LVAD patients.
– Hemolysis is most probably dependent on the pump design,
whose shear forces affect the red blood cells when they pass
through the pump (43).
Mechanical Assistance as Definitive
Therapy – Current Status
The improvement related to the use of latest generation VADs has
led us to reconsider the clinical care path of patients with terminal
heart failure. Assistance may be short, medium, or long term and
should have as its aim the recovery of cardiac function (bridge to
recovery) or transplantation (bridge to transplantation). Using an
axial pump, patients can remain implanted for long periods (years)
and time of a transplant can be decided upon with greater care.
Older patients (60–65 years) are typically placed lower on trans-
plant lists. They are usually severely symptomatic, require frequent
hospitalization, have a poor quality of life and a poor prognosis
(1–2 years) (32). Therefore, they have few hopes to be transplanted
and in case they would be, it will be with “marginal hearts.” Even
in these hard cases, there is a clear indication of continuous-flow
VAD implantation as definitive therapy or at least for the long-
term (such as “destination therapy” and “bridge to life”). Similarly,
patients who have an absolute contraindication to transplantation
or relative (pulmonary hypertension, systemic diseases, cancer
already made, etc.) have a well-defined indication for long-term
VAD implantation (15, 28).
The financing of VAD as destination therapy and heart trans-
plantation has to be considered in the global context of heart
failure treatment. Essentially, various national reimbursement
systems fear that with the establishment of alternative cardiac
replacement procedures, a new considerable cost-push will be
expected from the healthcare premium payers. However, the costs
of LVAD procedures are lower compared to the costs generated
not only by patients who undergo cardiac transplantation but
also by patients with advanced heart failure that need complex
multi-therapies, continue assistance, and several hospitalizations
a year (22, 44).
The DAVID Study and Conclusions
Given the recent technological developments and the results in
terms of quality and duration of life that can be obtained with
the latest generation of VADs, we wonder what will be their use
in the near future and if they ever will be preferred over cardiac
allografts. The rapid development in terms of miniaturization,
reliability, biocompatibility, and flexibility, bring them closer to
the characteristics of an “ideal VAD” (Table 7). New encouraging
results have been obtained from clinical trials: the latest data from
INTERMACS 2014 suggest that the survival rate at 2 years after
implantation is analogous to that of the transplanted heart (45).
The absence of large and well-designed prospective trials demon-
strating unequivocally the effectiveness and efficiency of the new
VADs makes it still difficult to convince cardiologists to direct
their patients to VAD implantation and administrators to fund
programs (22, 44). Several long-term studies are currently being
pursued worldwide for different LVAD implanted for long-term
or destination therapy (45, 46).
The Dispositivo di Assistenza Ventricolare ed Immissione
a Domicilio (DAVID=Ventricular Assist Device and Back to
Home) is an Italian multicenter prospective observational study
intended to assess the survival, quality of life, and economic
impact of axial pumps used as “Destination Therapy” and “Bridge
to Life.” The mechanical assist device chosen was the Jarvik 2000
Flowmaker®. Due to its major characteristics (small size, “min-
imally invasive” implantation without extracorporeal circulation
TABLE 7 | Characteristics of an ideal implantable ventricular assist device.
Characteristics of an ideal implantable ventricular assist system
Biocompatible
Small
Absence of percutaneous lines
Reliable (10,000,000 beats/year or four billion rounds/year)
Low-energy consumption
Easy to implant and explant
Allowing quick discharge
Low cost
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system and a retro-auricular driveline) it seemed to be particularly
suitable for long-term assistance (Destination Therapy).
The study protocol include patients with end-stage heart failure
who were not candidates for transplantation due to exceeding the
age limit or the presence of specific medical conditions and/or
hemodynamic. Contraindications for implantation of the VAD
were moderate-to-severe right ventricular insufficiency, severe
renal failure, or cancer with a poor prognosis of <2 years.
The study, which was led by our Center, was launched in
June 2006. To date (December 2014), 143 consecutive patients
were enrolled and underwent implantation of the Jarvik 2000®
TABLE 8 | Clinical and instrumental data of patients enrolled in a prospec-
tive, multicenter, observational study (DAVID).
Demographic
Implantations overall (n) 143
Gender (M/F) 123/20
Adult patients (n) 134
Pediatric patients (n) 9
Average age adult patients (years) 62 [29–75]
Median age adult patients (years) 61
Average age pediatric patients (years) 15
BSA adult patients (m2) 1.9 [1.17–2.36]
BSA patients pediatrics (m2) 1.6 [1.4–1.68]
Etiology
Idiopathic dilated cardiomyopathy 53 (37%)
Post-ischemic cardiomyopathy 76 (53%)
Othera 14 (10%)
Pre-implantation instrumental cardiac function evaluation
Cardiac index (l/minm2) 1.90.4
Systolic pulmonary artery pressure (mmHg) 5216
Pulmonary artery wedge pressure (mmHg) 239
Pulmonary vascular resistance (WU) 4.32.2
ECHO left ventricular end diastolic diameter (mm) 7312
ECHO ejection fraction (%) 215
TAPSE – tricuspid annular plane systolic excursion (mm) 164
INTERMACS level 3.01.2
Data are expressed as meanSD. Square bracketed are the maximum and minimum
values.
a In particular, pediatric patients with five Duchenne muscular dystrophy cases, three
hypertrophic cardiomyopathy, and one congenital muscular dystrophy.
Flowmaker. The operations took place in 18 Italian Cardiac
Surgery Centers. Of the 143 patients, 9 patients were under the age
of 18 years. As for adults, the average agewas 62 years (29–75). The
main demographic, clinical, and instrumental data are reported in
Table 8.
The implantation of the VAD was preferably performed with
a minimally invasive procedure, using a left lateral thoracotomy
without the use of extracorporeal circulation and with the driv-
eline connected with a retro-auricular pedestal; in some cases,
it was necessary to use extracorporeal circulation and a lon-
gitudinal median sternotomy due to hemodynamic instability
and/or the need for associated procedures (tricuspid repair and/or
mitral stenosis, aortic valve replacement, and ventricular repairs)
(Table 9).
The assessment of the duration of the assistance to date
(December 2014) is detailed in Table 10. Fifty-eight patients
have been enjoying ventricular assistance for more than 1 year, 35
patients have been enjoying ventricular assistance for more than
2 years, 15 patients for over 3 years of support, 8 patients for over
4 years of support, and 1 has surpassed 5 years. The total duration
of the assistance was >180 years/patient. During this period, no
malfunction of the device was registered thus confirming the high
reliability of the Jarvik 2000.
Of the 143 patients implanted, a total of 23 died before dis-
charge, earlier than 1month after surgery, with an intra-operative
TABLE 9 | Surgical implantation technique.
Surgical entry Off cardiopulmonary
bypass 81 (57%)
On cardiopulmonary
bypass 62 (43%)
Left thoracotomy 110 (77%) 95 (87%) 15 (13%)
Sternotomy 33 (23%) 1 (3%) 32 (97%)
TABLE 10 | Duration of care with in patients enrolled in the DAVID study.
Cumulative time on system (years) 183.6
Average time on system (days) 440
Average time on system of patients discharged out of hospital (days) 594
FIGURE 9 | Survival curves of patients included in the DAVID protocol, given the reported survival in the INTERMAS 2011 (45). Blue line= subjects who
underwent implantation of the device (n= 143). Red line= survival of those discharged (n= 105).
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FIGURE 10 | Evaluation of quality of life in patients with Jarvik 2000
via SF-36 questionnaire: graphs are presented as following; SF-36
score (in upper left), SF-36 norm-based score (upper right), and
SF-36 summaries (bottom) at 9months from Implant of the Jarvik
2000®. PF, physical functioning; RP, physical role; BP, bodily pain; GH,
general health; VT, vitality; SF, social functioning; RE, emotional role; MH,
mental health; PCS, physical health component summary; MCS, mental
health component summary.
FIGURE 11 | The multidisciplinary integration, as well as the
technological evolution of VAD will be essential in the coming years to
compare treatment of mechanical assist devices to transplantation in
terms of survival and quality of life.
mortality of 15.5%, 105 patients were discharged with survival of
82, 60 and 54%, respectively, at 1, 2, and 3 years after implanta-
tion [the remaining 15 patients were either transplanted before
discharge (5) or died in hospital (10)].
Figure 9 shows the survival curve of patients with Jarvik 2000®
in themedium-long term, a similar survival curve to that reported
by the INTERMACS 2014 study (45).
The assessment of quality of life (QoL) in patients with
Jarvik 2000® was carried out with the SF-36 questionnaire: a
multidimensional survey divided into 36 questions that allows
an in-depth analysis of the various physical and psychological
components. The questionnaire was administered to patients at 3,
6, and 9months after implantation of the Jarvik 2000®. Figure 10
shows the scores obtained at 9months of implantation of the
VAD for individual components, component summary physical
health component summary (PCS) and mental health component
summary (MCS). These values are normalized and compared
with the values obtainable in a healthy population with the same
characteristics of age and gender distribution.
The most obvious improvements concern the field of physical
health, expressed as the ability to carry out activities without
limitations due to the physical condition and with the absence
of pain. These are seen between the third and the sixth month
from implantation. At 9months from implantation all parameters
examined were showing improvements, thus validating VAD’s
capability for real Bridge to Life.
As we wait for the final results, it is necessary for us to opti-
mize the clinical care strategy of patients who undergo VAD
implantation. We stress the need for a multidisciplinary approach
to the patient with end-stage heart failure, with close collab-
oration between various professionals in order to improve all
phases of therapy (Figure 11): from design to production of more
biocompatible devices, to pre-implant evaluation systems, from
postoperative management to the reintegration of the patient
into an active and productive life. This approach is probably
the most important key factor toward full implementation and
success for this challenging and fascinating new therapeutic
frontier.
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